Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Lai, Nai Ming ^a,b   Chaiyakunapruk, Nathorn ^c,d   Lai, Nai An ^e   O'Riordan, Elizabeth ^f   Pau, Wilson Shu Cheng ^g   Saint, Sanjay ^h  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b TAYLOR S UNIVERSITY   (Malaysia)

^c MONASH UNIVERSITY MALAYSIA   (Malaysia)

^d NARESUAN UNIVERSITY   (Thailand)

^e QUEEN ELIZABETH II JUBILEE HOSPITAL   (Australia)

^f CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^g Hospital Tuanku Jaafar   (Malaysia)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZALKONIUM; CARBON; CEFAZOLIN; CHLORHEXIDINE; FLUOROURACIL; HEPARIN; MICONAZOLE; MINOCYCLINE; PLATINUM; RIFAMPICIN; SILVER; SULFADIAZINE; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; BLOOD CULTURE; CATHETER IMPREGNATION; CATHETER INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; DEVICE FAILURE; HEALTH CARE COST; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDICAL PROCEDURES; MORTALITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SILVER IMPREGNATION; SYSTEMATIC REVIEW; ADVERSE EFFECTS; CATHETER-RELATED INFECTIONS;

ADULT; ANTI-INFECTIVE AGENTS; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84961956858     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007878.pub3     Document Type: Review

References (162)

1. Abdelkefi A, Achour W, Ben Othman T, Ladeb S, Torjman L, Lakhal A, et al. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. Journal of Supportive Oncology 2007;5(6):273-8. [PUBMED: 17624052]
2. Antonelli M. Comparison of central venous catheters with silver nanoparticles versus conventional catheters (NanoAgCVC). www.clinicaltrials.gov 13 May 2011.
3. Antonelli M, De Pascale G, Ranieri V M, Pelaia P, Tufano R, Piazza O, et al. Comparison of triple-lumen central venous catheters impregnated with silver nanoparticles (AgTive®) vs conventional catheters in intensive care unit patients. Journal of Hospital Infection 2012;82:101-7.
4. Arvaniti K, Lathyris D, Clouva-Molyvdas P, Haidich AB, Mouloudi E, Synnefaki E, et al. Comparison of Oligon catheters and chlorhexidine-impregnated sponges with standard multilumen central venous catheters for prevention of associated colonization and infections in intensive care unit patients: a multicenter, randomized, controlled study. Critical Care Medicine 2012;40(2):420-9. [PUBMED: 21926583]
5. Babycos CR, Barrocas A, Webb WR. A prospective randomized trial comparing the silver-impregnated collagen cuff with the bedside tunneled subclavian catheter. Journal of Parenteral and Enteral Nutrition 1993;17(1):61-3. [PUBMED: 8437326]
6. Bach A, Darby D, Bottiger B, Bohrer H, Motsch J, Martin E. Retention of the antibiotic teicoplanin on a hydromer-coated central venous catheter to prevent bacterial colonization in postoperative surgical patients. Intensive Care Medicine 1996;22(10):1066-9. [PUBMED: 8923071]
7. Bach A, Schmidt H, Bottiger B, Schreiber B, Bohrer H, Motsch J, et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. Journal of Antimicrobial Chemotherapy 1996;37(2):315-22. [PUBMED: 8707741]
8. Bach A, Eberhardt H, Frick A, Schmidt H, Bottiger BW, Martin E. Efficacy of silver-coating central venous catheters in reducing bacterial colonization. Criticical Care Medicine 1999;27(3):515-21. [PUBMED: 10199530]
9. Bennegard K, Curelaru I, Gustavsson B, Linder LE, Zachrisson BF. Material thrombogenicity in central venous catheterization. I. A comparison between uncoated and heparin-coated, long antebrachial, polyethylene catheters. Acta Anaesthesiology Scandinavia 1982;26(2):112-20. [PUBMED: 7048839]
10. Bong JJ, Kite P, Wilco MH, McMahon MJ. Prevention of catheter related bloodstream infection by silver iontophoretic central venous catheters: a randomised controlled trial. Journal of Clinical Pathology 2003;56:731-5. [PUBMED: 14514774]
11. Boswald M, Lugauer S, Regenfus A, Braun GG, Martus P, Geis C, et al. Reduced rates of catheter-associated infection by use of a new silver-impregnated central venous catheter. Infection 1999;27 Suppl 1:S56-60. [PUBMED: 10379447]
12. Guggenbichler JP, Boswald M, Lugauer S, Bechert T, Krall T. Silver-impregnation reduces the risk of catheter related blood stream infections. Klinikarzt 1998;27(7-8):197-202.
13. Brun-Buisson C, Doyon F, Sollet JP, Cochard JF, Cohen Y, Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Medicine 2004;30(5):837-43. [PUBMED: 15060765]
14. Camargo LF, Marra AR, Buchele GL, Sogayar AM, Cal RG, De Sousa JM, et al. Double-lumen central venous catheters impregnated with chlorhexidine and silver sulfadiazine to prevent catheter colonization in the intensive care unit setting: a prospective randomized study. Journal of Hospital Infections 2009;72(3):227-33. [PUBMED: 19443078]
15. Carrasco MN, Bueno A, De las Cuevas C, Jimenez S, Salinas I, Sartorius A, et al. Evaluation of a triple-lumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Medicine 2004;30(4):633-8. [PUBMED: 14722639]
16. Ciresi DL, Albrecht RM, Volkers PA, Scholten DJ. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. American Surgeon 1996;62(8):641-6. [PUBMED: 8712561]
17. Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. Chest 1999;115(6):1632-40. [PUBMED: 10378561]
18. Corral L, Nolla-Salas M, Ibanez-Nolla J, Leon MA, Diaz RM, Cruz Martin M, et al. A prospective, randomized study in critically ill patients using the Oligon Vantex catheter. Journal of Hospital Infection 2003;55:212-9. [PUBMED: 14572489]
19. Darouiche RO, Raad II, Heard SO, Thornby JI, Wenker OC, Gabrielli A, et al. Catheter Study Group. A comparison of two antimicrobial-impregnated central venous catheters. New England Journal of Medicine 1999;340(1):1-8. [PUBMED: 9878638]
20. Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. American Journal of Infection Control 2003;31(1):1-8. [PUBMED: 12548250]
21. Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall MJ Jr, Metzler MH, et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Annals of Surgery 2005;242(2):193-200. [PUBMED: 16041209]
22. Dunser MW, Mayr AJ, Hinterberger G, Florl CL, Ulmer H, Schmid S, et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesthesia Analgesia 2005;101(6):1778-84. [PUBMED: 16301258]
23. Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware R. A prospective, randomized trial of rifampicin-minocycline-coated and silver-platinum-carbon-impregnated central venous catheters. Critical Care Medicine 2006;34(3):668-75. [PUBMED: 16505651]
24. George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. European Journal of Anaesthesiology 1997;14(4):428-31. [PUBMED: 9253572]
25. Goldschmidt H, Hahn U, Salwender HJ, Haas R, Jansen B, Wolbring P, et al. Prevention of catheter-related infections by silver coated central venous catheters in oncological patients. Zentralblatt fur Bakteriologie 1995;283(2):215-23. [PUBMED: 8825113]
26. Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. Journal of Clinical Oncology 2004;22(15):3163-71. Erratum in: Journal of Clinical Oncology 2005; 23 (15): 3652. [PUBMED: 15284269]
27. Hannan M, Juste RN, Umasanker S, Glendenning A, Nightingale C, Azadian B, et al. Antiseptic-bonded central venous catheters and bacterial colonization. Anaesthesia 1999;54(9):868-72. [PUBMED: 10460558]
28. Harter C, Salwender HJ, Bach A, Egerer G, Goldschmidt H, Ho AD. Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters. Cancer 2002;94(1):245-51. [PUBMED: 11815983]
29. Heard SO, Wagle M, Vijayakumar E, McLean S, Brueggemann A, Napolitano LM, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Archives of Internal Medicine 1998;158(1):81-7. [PUBMED: 9437382]
30. Jaeger K, Osthaus A, Heine J, Ruschulte H, Kuhlmann C, Weissbrodt H, et al. Efficacy of a benzalkonium chloride-impregnated central venous catheter to prevent catheter-associated infection in cancer patients. Chemotherapy 2001;47(1):50-5. [PUBMED: 11125233]
31. Jaeger K, Zenz S, Juttner B, Ruschulte H, Kuse E, Heine J, et al. Reduction of catheter-related infections in neutropenic patients: a prospective controlled randomized trial using a chlorhexidine and silver sulfadiazine-impregnated central venous catheter. Annals of Hematology 2005;84(4):258-62. [PUBMED: 15549302]
32. Kahveci F, Kaya FN, Osma S, Kutlay O. Influence of antiseptic-impregnated central venous catheters on catheter colonization and catheter-related bacteremia incidences in patients receiving TPN. Turk Anesteziyoloji ve Reanimasyon Dernegi Dergisi (Journal of Turkish Society of Anaesthesiology) 2005;33(4):321-7.
33. Kalfon P, De Vaumas C, Samba D, Boulet E, Lefrant JY, Eyraud D, et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Critical Care Medicine 2007;35(4):1032-9. [PUBMED: 17334256]
34. Kamal GD, Pfaller MA, Rempe LE, Jebson PJ. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA 1991;265(18):2364-8. [PUBMED: 2016833]
35. Leon C, Ruiz-Santana S, Rello J, De la Torre MV, Valles J, Alvarez-Lerma F, et al. Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Medicine 2004;30(10):1891-9. [PUBMED: 15278273]
36. Logghe C, Van Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. Journal of Hospital Infections 1997;37(2):145-56. [PUBMED: 9364263]
37. Maki DG, Cobb L, Garman JK, Shapiro JM, Ringer M, Helgerson RB. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. American Journal of Medicine 1988;85(3):307-14. [PUBMED: 3046351]
38. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Annals of Internal Medicine 1997;127(4):257-66. [PUBMED: 9265424]
39. Marik PE, Abraham G, Careau P, Varon J, Fromm RE Jr. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Critical Care Medicine 1999;27(6):1128-31. [PUBMED: 10397217]
40. Mer M, Duse AG, Galpin JS, Richards GA. Central venous catheterization: a prospective, randomized, double-blind study. Clinical and Applied Thrombosis/Hemostasis 2009;15(1):19-26. [PUBMED: 18593746]
41. Moretti EW, Ofstead CL, Kristy RM, Wetzler HP. Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia. Journal of Hospital Infection 2005;61(2):139-45. [PUBMED: 16026898]
42. Moss HA, Tebbs SE, Faroqui MH, Herbst T, Isaac JL, Brown J, et al. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. European Journal of Anaesthesiology 2000;17(11):680-7. [PUBMED: 11029566]
43. Osma S, Kahveci SF, Kaya FN, Akalin H, Ozakin C, Yilmaz E, et al. Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit. Journal of Hospital Infection 2006;62(2):156-62. [PUBMED: 16307824]
44. Ostendorf T, Meinhold A, Harter C, Salwender H, Egerer G, Geiss HK, et al. Chlorhexidine and silver-sulfadiazine coated central venous catheters in haematological patients--a double-blind, randomized, prospective, controlled trial. Supportive Care in Cancer 2005;13(12):993-1000. [PUBMED: 15834740]
45. Pemberton LB, Ross V, Cuddy P, Kremer H, Fessler T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters. A prospective randomized trial. Archives of Surgery 1996;131(9):986-9. [PUBMED: 8790170]
46. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. The Texas Medical Center Catheter Study Group. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Annals of Internal Medicine 1997;127(4):267-74. [PUBMED: 9265425]
47. Raad II, Darouiche RO, Hachem R, Abi-Said D, Safar H, Darnule T, et al. Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. Critical Care Medicine 1998;26(2):219-24. [PUBMED: 9468157]
48. Ranucci M, Isgrò G, Giomarelli PP, Pavesi M, Luzzani A, Cattabriga I, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Critical Care Medicine 2003;31(1):52-9. [PUBMED: 12544993]
49. Rupp ME, Lisco SJ, Lipsett PA, Perl TM, Keating K, Civetta JM, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Annals of Internal Medicine 2005;143(8):570-80. [PUBMED: 16230723]
50. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagnostic Microbiology and Infectious Disease 2000;38(1):1-5. [PUBMED: 11025176.]
51. Sherertz RJ, Heard SO, Raad II, Gentry L, Bowton D, Scuderi P, et al. Gamma radiation-sterilized, triple-lumen catheters coated with a low concentration of chlorhexidine were not efficacious at preventing catheter infections in intensive care unit patients. Antimicrobial Agents and Chemotherapy 1996;40(9):1995-7. [CENTRAL: CN-00132224]
52. Smith HO, DeVictoria CL, Garfinkel D, Anderson P, Goldberg GL, Soeiro R, et al. A prospective randomized comparison of an attached silver-impregnated cuff to prevent central venous catheter-associated infection. Gynaecologic Oncology 1995;58(1):92-100. [PUBMED: 7789897]
53. Stoiser B, Kofler J, Staudinger T, Georgopoulos A, Lugauer S, Guggenbichler JP, et al. Contamination of central venous catheters in immunocompromised patients: a comparison between two different types of central venous catheters. Journal of Hospital Infection 2002;50(3):202-6. [PUBMED: 11886196]
54. Bach A. A randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections (comment). Archives of Surgery 1998;133(9):1022. [PUBMED: 9749860]
55. Tennenberg S, Lieser M, McCurdy B, Boomer G, Howington E, Newman C, et al. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Archives of Surgery 1997;132(12):1348-51. [PUBMED: 9403542]
56. Theaker C, Juste R, Lucas N, Tallboys C, Azadian B, Soni N. Comparison of bacterial colonization rates of antiseptic impregnated and pure polymer central venous catheters in the critically ill. Journal of Hospital Infection 2002;52(4):310-2. [PUBMED: 12473479]
57. Thornton J, Todd NJ, Webster NR. Central venous line sepsis in the intensive care unit. A study comparing antibiotic coated catheters with plain catheters. Anaesthesia 1996;51(11):1018-20. [PUBMED: 8967579]
58. Van Heerden PV, Webb SA, Fong S, Golledge CL, Roberts BL, Thompson WR. Central venous catheters revisited--infection rates and an assessment of the new Fibrin Analysing System brush. Anaesthesia and Intensive Care 1996;24(3):330-3. [PUBMED: 8805887]
59. Van Vliet J, Leusink JA, De Jongh BM, De Boer A. A comparison between two types of central venous catheters in the prevention of catheter-related infections: the importance of performing all the relevant cultures. Clinical Intensive Care 2001;12(3):135-40. [EMBASE: 2001264184]
60. Walz JM, Avelar RL, Longtine KJ, Carter KL, Mermel LA, Heard SO. Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. Critical Care Medicine 2010;38(11):2095-102. [PUBMED: 20711070]
61. Schierholz JM, Nagelschmidt K, Nagelschmidt M, Lefering R, Yucel N, Beuth J. Antimicrobial central venous catheters in oncology: efficacy of a rifampicin-miconazole-releasing catheter. Anticancer Research 2010;30(4):1353-8. [PUBMED: 20530452]
62. Yucel N, Lefering R, Maegele M, Max M, Rossaint R, Koch A, et al. Reduced colonization and infection with miconazole-rifampicin modified central venous catheters: a randomized controlled clinical trial. Journal of Antimicrobial Chemotherapy 2004;54(6):1109-15. [PUBMED: 15537696]
63. Alderman RL, Sugarbaker PH. Prospective non randomized trial of silver impregnated cuff central lines. International Surgery 2005;90(4):219-22. [PUBMED: 16548318]
64. Al-Hwiesh AK. Tunneled catheter-antibiotic lock therapy for prevention of dialysis catheter-related infections: a single center experience. Saudi Journal of Kidney Diseases and Transplantation 2008;19(4):593-602. [PUBMED: 18580019]
65. Al-Hwiesh AK, Abdul-Rahman IS. Successful prevention of tunneled, central catheter infection by antibiotic lock therapy using vancomycin and gentamycin. Saudi Journal of Kidney Diseases and Transplantation 2007;18(2):239-47. [PUBMED: 17496402]
66. Alonso-Echanove J, Edwards JR, Richards MJ, Brennan P, Venezia RA, Keen J, et al. Effect of nurse staffing and antimicrobial-impregnated central venous catheters on the risk for bloodstream infections in intensive care units. Infection Control and Hospital Epidemiology 2003;24(12):916-25. [PUBMED: 14700407]
67. Anton N, Cox PN, Massicotte MP, Chait P, Yasui Y, Dinyari PM, et al. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial. Pediatrics 2009;123(3):e453-8. [PUBMED: 19237438]
68. Bambauer R, Mestres P, Schiel R, Schneidewind JM, Goudjinou R, Latza R, et al. Surface treated large bore catheters with silver based coatings versus untreated catheters for extracorporeal detoxification methods. American Society for Artificial Internal Organs (ASAIO) Journal 1998;44(4):303-8. [PUBMED: 9682957]
69. Bambauer R, Mestres P, Schiel R, Schneidewind JM, Latza R, Bambauer S, et al. Surface treated catheters with ion beam based process for blood access. Therapeutic Apheresis and Dialysis 2000;4(5):342-7. [PUBMED: 11111815]
70. Betjes MG, Van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrology Dialysis Transplantation 2004;19(6):1546-51. [PUBMED: 14993498]
71. Borschel DM, Chenoweth CE, Kaufman SR, Hyde KV, Van Der Elzen KA, Raghunathan TE, et al. Are antiseptic-coated central venous catheters effective in a real-world setting?. American Journal of Infection Control 2006;34(6):388-93. [PUBMED: 16877109]
72. Carbon RT, Lugauer S, Geitner U, Regenfus A, Boswald M, Greil J, et al. Reducing catheter-associated infections with silver-impregnated catheters in long-term therapy of children. Infection 1999;27 Suppl 1:S69-73. [PUBMED: 10379449]
73. Casey AL, Karpanen TJ, Nightingale P, Cook M, Elliott TSJ. Microbiological comparison of a silver-coated and a non-coated needleless intravascular connector in clinical use. Journal of Hospital Infection 2012;80:299-303.
74. Chaftari AM, Kassis C, El Issa H, Al Wohoush I, Jiang Y, Rangaraj G, et al. Novel approach using antimicrobial catheters to improve the management of central line-associated bloodstream infections in cancer patients. Cancer 2011;117(11):2551-8. [EMBASE: 1097-0142]
75. Chatzinikolaou I, Finkel K, Hanna H, Boktour M, Foringer J, Ho T, et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. American Journal of Medicine 2003;115(5):352-7. [PUBMED: 14553869]
76. Chelliah A, Heydon KH, Zaoutis TE, Rettig SL, Dominguez TE, Lin R, et al. Observational trial of antibiotic-coated central venous catheters in critically ill paediatric patients. Pediatric Infectious Disease Journal 2007;26(9):816-20. [PUBMED: 17721377]
77. Cherry-Bukowiec JR, Denchev K, Dickinson S, Chenoweth CE, Zalewski C, Meldrum, C, et al. Prevention of catheter-related blood stream infection: back to basics?. Surgical Infections 2011;12(1):27-32. [PUBMED: 21171811]
78. Cherry-Bukowiec JR, Denchev KL, Dickinson S, Chenoweth C, Zalewski C, Meldrum C, et al. Prevention of catheter-related sepsis: back to basics?. Surgical Infections 2009;10(2):207.
79. Dahlberg PJ, Agger WA, Singer JR, Yutuc WR, Newcomer KL, Schaper A, et al. Subclavian hemodialysis catheter infections: a prospective, randomized trial of an attachable silver-impregnated cuff for prevention of catheter-related infections. Infection Control and Hospital Epidemiology 1995;16(9):506-11. [PUBMED: 8537627]
80. Frank U, Chojnacki T, Dettenkofer M, Daschner FD. Cost-effectiveness of an antiseptic-impregnated central venous catheter in the ICU. Intensive Care Medicine 2003;29(1):139. [PUBMED: 12528036]
81. Garland JS, Alex CP, Mueller CD, Otten D, Shivpuri C, Harris MC, et al. A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonates. Pediatrics 2001;107(6):1431-6. [PUBMED: 11389271]
82. Geyik SG, Gursoy B, Sancak B, Arikan S, Yorganci K. In vitro antifungal activities of antimicrobial coated/impregnated central venous catheters against Candida albicans. Journal of Medical and Surgical Intensive Care Medicine 2010;1(1):10-3. [EMBASE: 2011123033]
83. Guggenbichler JP, Juhl G, Braun GG, Frass M, Kunstle OA, Plotz J, et al. Clinical investigation of a new central venous catheter impregnated with silver nanoparticles. Hygiene & Medizin (Hygiene and Medicine) 2003;28(6):228-42. [EMBASE: 2003275496]
84. Halton KA, Cook DA, Whitby M, Paterson DL, Graves N. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Critical Care 2009;13(2):R35. [PUBMED: 19284570]
85. Hanley EM, Veeder A, Smith T, Drusano G, Currie E, Venezia RA. Evaluation of an antiseptic triple-lumen catheter in an intensive care unit. Critical Care Medicine 2000;28(2):366-70. [PUBMED: 10708168]
86. Hanna HA, Raad II, Hackett B, Wallace SK, Price KJ, Coyle DE, et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest 2003;124(3):1030-8. [PUBMED: 12970034 ]
87. Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Annals of Hematology 2012;91:613-20.
88. Jacob J, Tejedor SC, Reyes MD, Switchenko J, Easley K, Garrett G, et al. Comparison of a novel silver-coated catheter access device and a standard catheter access device: a dual center cross-over study. 49th Annual Conference of the Infectous Disease Society of America (IDSA); 2011 October 20-23; Boston. Boston: IDSA, 2011:Abstract no 676.
89. Jansen B, Kristinsson KG, Jansen S, Peters G, Pulverer G. In-vitro efficacy of a central venous catheter complexed with iodine to prevent bacterial colonization. Journal of Antimicrobial Chemotherapy 1992;30(2):135-9. [PUBMED: 1399922]
90. Jung YJ, Koh Y, Lim CM, Lee JS, Yu H, Oh YM, et al. The central venous catheter-related infection of chlorhexidine-silver sulfadiazine coated catheters in medical ICU. Tuberculosis and Respiratory Diseases 2005;59(4):389-96.
91. Khare MD, Bukhari SS, Swann A, Spiers P, McLaren I, Myers J. Reduction of catheter-related colonization by the use of a silver zeolite-impregnated central vascular catheter in adult critical care. Journal of Infection 2007;54(2):146-50. [PUBMED: 16678904]
92. Krafte-Jacobs B, Sivit CJ, Mejia R, Pollack MM. Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding. Journal of Pediatrics 1995;126(1):50-4. [PUBMED: 7815223]
93. Lenz AM, Vassallo JC, Moreno GE, Althabe M, Gomez S, Magliola R, et al. Prevention of catheter-related infection; usefulness and cost-effectiveness of antiseptic catheters in children. Archivos Argentinos de Pediatria 2010;108(3):209-15. [PUBMED: 20544135]
94. Levy I, Katz J, Solter E, Samra Z, Vidne B, Birk E, et al. Chlorhexidine-impregnated dressing for prevention of colonization of central venous catheters in infants and children: a randomized controlled study. Pediatric Infectious Disease Journal 2005;24(8):676-9. [PUBMED: 16094219]
95. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Critical Care Medicine 2000;28(9):3332-8. [PUBMED: 11008998 ]
96. Misra A, Thatte W S, Ambike D. A comparative study of the microbial and clinical outcome of antimicrobial surface treated central venous catheters exchanged over the guide wire versus newly inserted catheters. Indian Journal of Critical Care Medicine 2014;18:S2.
97. Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Medicine 2000;26(7):967-72. [PUBMED: 10990114]
98. Richards B, Chaboyer W, Bladen T, Schluter PJ. Effect of central venous catheter type on infections: a prospective clinical trial. Journal of Hospital Infection 2003;54(1):10-7. [PUBMED: 12767841]
99. Roberts B, Cheung D. Biopatch--a new concept in antimicrobial dressings for invasive devices. Australian Critical Care 1998;11(1):16-9. [PUBMED: 9708081]
100. Ruschulte H, Franke M, Gastmeier P, Zenz S, Mahr KH, Buchholz S, et al. Prevention of central venous catheter related infections with chlorhexidine gluconate impregnated wound dressings: a randomized controlled trial. Annals of Hematology 2009;88(3):267-72. [PUBMED: 18679683]
101. Schmitt SK, Knapp C, Hall GS, Longworth DL, McMahon JT, Washington JA. Impact of chlorhexidine-silver sulfadiazine-impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria. Journal of Clinical Microbiology 1996;34(3):508-11. [PUBMED: 8904403]
102. Schuerer DJ, Zack JE, Thomas J, Borecki IB, Sona CS, Schallom ME, et al. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial. Surgical Infection 2007;8(4):445-54. [PUBMED: 17883361]
103. Schutze GE. Antimicrobial-impregnated central venous catheters. Pediatric Infectious Disease Journal 2002;21(1):63-4. [PUBMED: 11791103]
104. Sherertz RJ, Stephens JL, Marosok RD, Carruth WA, Rich HA, Hampton KD, et al. The risk of peripheral vein phlebitis associated with chlorhexidine-coated catheters: a randomized, double-blind trial. Infection Control and Hospital Epidemiology 1997;18(4):230-6. [PUBMED: 9131364]
105. Timsit JF, Schwebel C, Vesin A, Bouadma L, Geffroy A, Garrouste-Orgeas M, et al. Cost-benefit of chlorhexidine impregnated sponges for prevention of catheter-related infections in adult ICU patients. Intensive Care Medicine 2010;36:S207.
106. Timsit JF, Francais A, L'Heriteau F, Coignard B, Venier AG, Jarno P, et al. Center, patient and catheter-related determinants of catheter-related infection in the ICU: a multicenter analysis based on a hierarchical model. Intensive Care Medicine 2010;36:S208.
107. Trerotola SO, Johnson MS, Shah H, Kraus MA, McKusky MA, Ambrosius WT, et al. Tunneled hemodialysis catheters: use of a silver-coated catheter for prevention of infection--a randomized study. Radiology 1998;207(2):491-6. [PUBMED: 9577500]
108. Vokurka S, Kabatova-Maxova K, Skardova J, Bystricka E. Antimicrobial chlorhexidine/silver sulfadiazine-coated central venous catheters versus those uncoated in patients undergoing allogeneic stem cell transplantation. Supportive Care in Cancer 2009;17(2):145-51. [PUBMED: 18449570]
109. Wong GK, Ip M, Poon WS, Mak CW, Ng RY. Antibiotics-impregnated ventricular catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF infections: a prospective randomized clinical trial. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81(10):1064-7. [PUBMED: 20466698]
110. Ye X, Rupnow M, Bastide P, Lafuma A, Ovington L, Jarvis WR. Economic impact of use of chlorhexidine-impregnated sponge dressing for prevention of central line-associated infections in the United States. American Journal of Infection Control 2011;39(8):647-54. [PUBMED: 21641681]
111. Yorganci K, Krepel C, Weigelt JA, Edmiston CE. Activity of antibacterial impregnated central venous catheters against Klebsiella pneumoniae. Intensive Care Medicine 2002;28(4):438-42. [PUBMED: 11967598 ]
112. Krikava I, Kolar M, Garajova B, Balik T, Sevcikova A, Pachl J, et al. Polyhexanide anti-infective coating of central venous catheters in prevention of catheter colonization and bloodstream infection: Study HC-G-H-0507. Critical Care 2011;15:P229.
113. Pachl J, Sevcik P, Brauer B. Rate of catheter colonization and risk of bloodstream infection during use of two different central venous catheters (CVC). www.clinicaltrials.gov 4 February 2010.
114. Abdelkefi A, Achour W, Ben Othman T, Ladeb S, Torjman L, Lakhal A, et al. Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. The Journal of Supportive Oncology 2007;5(6):273-8. [PUBMED: 17624052]
115. Centers for Disease Control and Prevention. Antibiotic/Antimicrobial resistance: glossary. Centers for Disease Control and Prevention health topics 22 July 2010.
116. O'Grady N, Alexander M, Burns LA, Dellinger P, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections, 2011. Centers for Disease Control and Prevention (CDC), Healthcare Infection Control Practices Advisory Committee (HICPAC) publications 1 April 2011.
117. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Annals of Internal Medicine 2002;136(11):792-801. [PUBMED: 12044127]
118. Cicalini S, Palmieri F, Petrosillo N. Clinical review: new technologies for prevention of intravascular catheter-related infections. Critical Care 2004;8:157-62. [PUBMED: 15153233]
119. Falagas ME, Fragoulis K, Bliziotis IA, Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. The Journal of Antimicrobial Chemotherapy 2007;59:359-69. [PUBMED: 17255143]
120. Gilbert RE, Harden M. Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review. Current Opinion in Infectious Diseases 2008;21(3):235-45. [PUBMED: 18448967]
121. Gnass SA, Barboza L, Bilicich D, Angeloro P, Treiyer W, Grenovero S, et al. Prevention of central venous catheter-related bloodstream infections using non-technologic strategies. Infection Control and Hospital Epidemiology 2004;25:675-7. [PUBMED: 15357160]
122. Hanna H, Bahna P, Reitzel R, Dvorak T, Chaiban G, Hachem R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrobial Agents and Chemotherapy 2006;50(10):3283-8. [PUBMED: 17005806]
123. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
124. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. The Cochrane Collaboration.
125. Hockenhull JC, Dwan K, Boland A, Smith G, Bagust A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation. Health Technology Assessment 2008;12:iii-92. [PUBMED: 18405471]
126. Hockenhull JC, Dwan KM, Smith GW, Gamble CL, Boland A, Walley TJ, et al. The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Critical Care Medicine 2009;37:702-12. [PUBMED: 19114884]
127. Hu KK, Lipsky BA, Veenstra DL, Saint S. Using maximal sterile barriers to prevent central venous catheter-related infection: a systematic evidence-based review. American Journal of Infection Control 2004;32(3):142-6. [PUBMED: 15153925]
128. Jung WK, Koo HC, Kim KW, Shin S, Kim SH, Park YH. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Applied and Environmental Microbiology 2008;74(7):2171-8. [PUBMED: 18245232]
129. Kang S, Pinault M, Pfefferle LD, Elimelech M. Single-walled carbon nanotubes exhibit strong antimicrobial activity. Langmuir 2007;23(17):8670-3. [PUBMED: 17658863]
130. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Medicine 2003;29(4):530-8. [PUBMED: 12664219]
131. McCann M, Moore ZEH. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006894.pub2]
132. McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection?. Clinical Infectious Diseases 2003;37:65-72. [PUBMED: 12830410]
133. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clinical Microbiology Reviews 1999;12(1):147-79. [PUBMED: 9880479]
134. Mermel LA. New technologies to prevent intravascular catheter-related bloodstream infections. Emerging Infectious Diseases 2001;7:197-9. [PUBMED: 11294705]
135. Narayan R, Abernathy H, Riester L, Berry C, Brigmon R. Antimicrobial properties of diamond-like carbon-silver-platinum nanocomposite thin films. Journal of Materials Engineering and Performance 2005;14:435-40. [DOI: 10.1361/105994905X56197]
136. Dudeck M, Horan T, Peterson K, Allen-Bridson K, Morrell G, Pollock D, et al. National Healthcare Safety Network (NHSN) Report, Data Summary for 2010, Device-associated Module. National Healthcare Safety Network (NHSN) Annual Reports 7 July 2011.
137. Niel-Weise BS, Stijnen T, Van den Broek PJ. Anti-infective-treated central venous catheters: a systematic review of randomized controlled trials. Intensive Care Medicine 2007;33:2058-68. [PUBMED: 17940746]
138. Niel-Weise BS, Stijnen T, Van den Broek PJ. Anti-infective-treated central venous catheters for total parenteral nutrition or chemotherapy: a systematic review. Journal of Hospital Infection 2008;69:114-23. [PUBMED: 18439717]
139. Norwood S, Ruby A, Civetta J, Cortes V. Catheter-related infections and associated septicemia. Chest 1991;99:968-75. [PUBMED: 2009804]
140. Olaechea PM, Palomar M, Alvarez-Lerma F, Otal JJ, Insausti J, Lopez-Pueyo MJ. Morbidity and mortality associated with primary and catheter-related bloodstream infections in critically ill patients. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 2013;26(1):21-9. [PUBMED: 23546458]
141. Peng S, Lu Y. Clinical epidemiology of central venous catheter-related bloodstream infections in an intensive care unit in China. Journal of Critical Care 2013;28(3):277-83. [PUBMED: 23265289]
142. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. The New England Journal of Medicine 2006;355:2725-32. [PUBMED: 17192537]
143. Raad II, Hohn DC, Gilbreath BJ, Suleiman N, Hill LA, Bruso PA, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infection Control and Hospital Epidemiology 1994;15:231-8. [PUBMED: 8207189]
144. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. Antimicrobial Agents and Chemotherapy 1995;39:2397-400. [PUBMED: 8585715]
145. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampicin. The Journal of Infectious Diseases 1996;173:418-24. [PUBMED: 8568304]
146. Raad II, Hanna HA. Intravascular catheter-related infections: new horizons and recent advances. Archives of Internal Medicine 2002;162(8):871-8. [PUBMED: 11966337]
147. Ramritu P, Halton K, Collignon P, Cook D, Fraenkel D, Battistutta D, et al. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. American Journal of Infection Control 2008;36:104-17. [PUBMED: 18313512 ]
148. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
149. Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. The Journal of Biological Chemistry 1967;242(6):1347-52. [PUBMED: 5337590]
150. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Annals of Internal Medicine 2006;145:582-91. [PUBMED: 17043340]
151. Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: are antimicrobial catheters useful?. Infection Control and Hospital Epidemiology 2000;21:375-80. [PUBMED: 10879567]
152. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infection Control and Hospital Epidemiology 2001;22:640-6. [PUBMED: 11776351]
153. Schmidt SK, Knapp C, Hall G, Longworth D, McMahon JT, Washington JA. Impact of chlorhexidine-silver sulfadiazine-Impregnated central venous catheters on in vitro quantitation of catheter-associated bacteria. Journal of Clinical Microbiology 1996;34:508-11. [PUBMED: 8904403]
154. Shah PS, Shah VS. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD002772.pub3]
155. Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates. The Journal of Hospital Infection 2009;72(2):97-103. [PUBMED: 19246122]
156. Timsit JF, Schwebel C, Bouadma L, Geffroy A, Garrouste-Orgeas M, Pease S, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA 2009;301(12):1231-41. [PUBMED: 19318651 ]
157. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281:261-7. [PUBMED: 9918482]
158. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282:554-60. [PUBMED: 10450717]
159. Walder B, Pittet D, Tramer MR. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis. Infection Control and Hospital Epidemiology 2002;23:748-56. [PUBMED: 12517018]
160. Webster J, Gillies D, O'Riordan E, Sherriff KL, Rickard CM. Gauze and tape and transparent polyurethane dressings for central venous catheters. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD003827.pub2]
161. Lai NM, Chaiyakunapruk N, Lai NA, O'Riordan E, Pau WS, Saint S. Catheter impregnation, coating or bonding for reducing central venous catheter related infections in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007878]
162. Lai NM, Chaiyakunapruk N, Lai NA, O'Riordan E, Pau WSC, Saint S. Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD007878.pub2]